101P - Concentrations of soluble form of epidermal growth factor (oncoprotein SP 185) in systemic therapy

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Anti-Cancer Agents & Biologic Therapy
Translational Research
Presenter Lola Alimkhodjaeva
Citation Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519
Authors L.T. Alimkhodjaeva, N. Makhmudova
  • Mammology, National Cancer Research Center of Uzbekistan, 100174 - Tashkent/UZ

Abstract

Aim/Background

Is to study the concentration of molecular markers capable to predict the disease outcome. A significant portion of cancer cells, including breast cancer expresses serum protein SP 185 (soluble receptor analogue Her2/neu). Significant increase SP 185 in blood serum has been already proved for 60 months before clinical manifestations of cancer. This means that the study of this marker can be of great importance for early detection of the disease.

Methods

The study included 145 patients with metastatic breast cancer: 56 patients with nonresectable primary breast cancer and 89 patients with recurrences and metastases after a previous comprehensive treatment. The average age of patients was 51.6 years. Dynamics of serum form concentrations of oncoprotein SP185 was studied before treatment and after two sessions of chemotherapy. The study was performed by ELISA on automated analyzer Brio-Sirio «Seac».

Results

A statistically significant correlation between SP 185 concentration changes and the type of therapeutic effect during systemic chemotherapy has been established. With a decrease in tumor size there is a decrease of concentration SP 185 (p = 0.006); the increase in tumor size grows the concentration of oncoprotein SP 185 (p = 0.013); in patients with stabilization of tumor process the lack of dynamics SP 185 concentrations in systemic treatment has been stated (p = 0.0748). Investigation continues.

Conclusions

It seems appropriate to further study of the diagnostic value of the changes in oncoprotein SP 185 concentration in blood serum of patients with advanced breast cancer to evaluate the tumor sensitivity to chemotherapy.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.